Nevada Coalition for Psychedelic Medicines

Home
United States
Honolulu, HI
Nevada Coalition for Psychedelic Medicines

Saving Lives | Revolutionizing Mental Health The Nevada Coalition for Psychedelic Medicines is dedicated to healing through the use of psychedelic substances.

We strive to increase access to and understanding of these substances as potential therapies for mental health and well-being and to eliminate the stigma and criminalization associated with their use. Through collaboration, advocacy, and education, we aim to improve the health and lives of individuals in our state and nation.

09/03/2026

The New Mexico Department of Health Center for Medical Cannabis and Ps𝒾𝓁𝑜cy𝒷𝒾𝓃 began accepting applications last week from potential producers to grow the mushrooms for future program participants. Cvitanovic told Source that the application is intended to ensure the ps𝒾𝓁𝑜cy𝒷𝒾𝓃 “produced for this program in New Mexico is both safe and medically beneficial for patients, as well as that this doesn’t cause safety issues for people in New Mexico generally.”

Check out the full article:
https://sfreporter.com/news/state-psilocybin-program-opens-permitting-applications-for-p/

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

09/02/2026

Miller emphasized that receptor binding alone does not determine a compound’s clinical effect; the subsequent functional activity generated within the intracellular environment following that binding is equally central to understanding how ps𝒾𝓁𝑜cy𝒷𝒾𝓃, LᦓD, and 𝓂𝑒sca𝓁𝒾𝓃𝑒 ultimately produce their effects. He positioned this binding-to-function distinction as a key pharmacodynamic principle for clinicians to understand as psꪗchꫀdeꪶic compounds move closer to potential regulatory approval and broader clinical use.

Check out the full article:
https://www.psychiatrictimes.com/view/lessons-from-psychedelics-on-binding-and-functional-activity

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/27/2026

The report published on Wednesday by the Substance Abuse and Mental Health Services Administration (SAMHSA) says that substances such as ps𝒾𝓁𝑜cy𝒷𝒾𝓃, LᦓD and M𝐷M𝐴 “show potential in clinical studies for treating depression, post-traumatic stress disorder, anxiety, and substance use disorders,” though it cautions that the evidence base “remains uneven and important methodological limitations persist.”

The SAMHSA report notes that President Donald Trump issued an executive order aimed at expanding and expediting research on the potential therapeutic benefits of psꪗchꫀdeꪶics in April with an eye toward federal approval of psꪗchꫀdeꪶic medications by the Food and Drug Administration (FDA).

State officials should “consider planning now for the fiscal, legal, and operational implications of potential FDA-approved psꪗchꫀdeꪶic therapies, including any Medicaid coverage obligations,” it says.

Check out the full article:
https://www.marijuanamoment.net/states-should-start-planning-now-for-fda-approval-of-psychedelics-federal-report-says/

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/25/2026

While adjustment disorder can develop in response to a range of life events, the study focuses on people whose symptoms occur in the context of a serious medical illness.

The study is being led by Anthony Rothschild, MD, the Irving S. and Betty Brudnick Chair in Psychiatry and professor of psychiatry & behavioral sciences, and brings together clinicians and researchers across multiple departments, including psychiatry, medicine and neurology.

Check out the full article:
UMass Chan researchers study psychedelic medication for adjustment disorder in people with serious medical conditions

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/24/2026

Nevada is at a pivotal moment as lawmakers consider how to responsibly bring psꪗchꫀdeꪶic-assisted therapies into the state’s healthcare system. The legislation discussed in the article reflects a growing effort to move beyond the long-standing stigma surrounding psꪗchꫀdeꪶics while establishing guardrails for research, clinical use and patient safety. The goal is not simply to make these substances available, but to create a framework grounded in evidence and responsible medical practice as research continues to develop.

UNLV neuroscientist Dustin Hines brings that scientific caution to the conversation. Hines has emphasized that psꪗchꫀdeꪶics show significant therapeutic promise, but that researchers are still working to understand precisely how they affect the brain, who is most likely to benefit and under what conditions they can be used safely. His work underscores an important distinction: promising results are not the same as a complete scientific understanding. For Hines, continued research is essential to turning the potential of psꪗchꫀdeꪶics into treatments that are evidence-based, safe and clinically effective.

Check out the full article here:
https://lasvegasweekly.com/news/2026/aug/20/psychedelics-could-offer-a-lifeline-for-nevada/

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/20/2026

The announcement of the hearing was made a day after FDA issued the long-awaited finalized guidance on “Psꪗchꫀdeꪶic Drugs: Considerations for Clinical Investigations” providing recommendations to sponsors on clinical trial design for this class of drugs.

Key Details:
Stakeholders across the pharmaceutical, healthcare, research, and investment sectors, as well as the broader medical community, should be aware of the following key details regarding the hearing:  Public Hearing:
* Date: September 14, 2026, from 12:30 p.m. to 4:30 p.m. ET
* Format: Hybrid (in-person and virtual webcast)

Critical Deadlines:
* Requests to Present Oral Comments: August 21, 2026, by 11:59 p.m. ET
* Written Comment Submission Deadline: October 5, 2026, by 11:59 p.m. ET
Written comments may be submitted electronically via regulations.gov.

Topics for Public Input:
FDA and its federal agency partners are seeking input on the potential future therapeutic use of psꪗchꫀdeꪶic drugs in supervised and supportive settings, organized around four key areas:
1. Provider training and credentialing
2. Promotion of patient safety
3. Considerations for access
4. Best practices for data collection and standardization

Check out the full article for more guidance:
https://foleyhoag.com/news-and-insights/publications/alerts-and-updates/2026/august/psychedelic-therapeutics-take-center-stage-fda-announces-public-hearing-and-finalizes-clinical/

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/18/2026

Numerous clinical trials indicate that i᥇oᧁainꫀ can upregulate markers of myelination under conditions of both opioid use disorder or MS.

I᥇oᧁainꫀ’s ability to produce these beneficial changes in the brain depend upon its complex actions at multiple neurotransmitter receptors. These complex actions reduce the glutamate toxicity and correct some metabolic processes leading to long-lasting neuroplasticity that facilitates neuronal repair and remyelination.

I᥇oᧁainꫀ joins a growing list of psꪗchꫀdeꪶic drugs that have been discovered to potentially produce beneficial effects on brain health and mood.

Check out the full article:
https://www.psychologytoday.com/us/blog/your-brain-on-food/202608/a-novel-benefit-of-the-psychedelic-ibogaine

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/12/2026

In addition to PIVOT, the VA has 20 other active trials observing the effect of psꪗchꫀdeꪶic drugs on mental health conditions. All trials are conducted in controlled clinical settings following US Food and Drug Administration (FDA) safety protocols and guidelines. Clinical therapies will not be used in practice settings until granted FDA approval.

Check out the full article:
https://www.hmpgloballearningnetwork.com/site/vht/news/va-announces-new-trial-assessing-impact-psilocybin-veterans-major-depressive-disorder

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/11/2026

Follow the link below to dive deeper into:
~ AOC, Other Members of Congress Tout Psꪗchꫀdeꪶic Benefits as Research Amendments Advance
~ VA Secretary Highlights Psꪗchꫀdeꪶic Progress
~ Louisiana Opioid Settlement Psꪗchꫀdeꪶic Pilot Launches

https://www.lucid.news/psychedelic-policy-briefing/

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

08/06/2026

Kimon de Greef is no stranger to underground economies, having spent years reporting on abalone poaching (Poacher) and other lesser-examined biotrades. Over the past half-decade, the South African journalist has trained that same analytical eye on 5-ℳ𝑒𝒪-DℳT, the potent and short-acting psꪗchꫀdeꪶic, culminating in his latest narrative non-fiction book, published today, Ego Trip.

It’s a fascinating read, full of fresh stories, angles, and anecdotes, a testament to de Greef’s rich field work and reporting, but also to the peculiarity of the molecule and the poachers, pharma execs, and seekers that are in its orbit.

Check out the full article:
https://psychedelicalpha.com/news/from-sonora-to-big-pharma-kimon-de-greef-traces-the-strange-rise-of-5-meo-dmt/

🛑18+ only. This content is for educational and harm-reduction purposes. We do not promote or support illegal activity, the sale or use of restricted substances, or the use of associated tools or accessories. Per Meta’s Community Standards, discussion of legality, research, and medical exploration is permitted. Not medical advice. Consult a qualified professional for health decisions.

Address

415 S Beretania St
Honolulu, HI
96813

Website

https://www.nevadacpm.org/

Alerts

Be the first to know and let us send you an email when Nevada Coalition for Psychedelic Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Nevada Coalition for Psychedelic Medicines:

Want your business to be the top-listed Health & Beauty Business in Honolulu?